BioSpace News Archive

Vaxxinity, Inc. today reported financial results for the first quarter ended March 31, 2022.

Brii Biosciences Limited today announced new data demonstrating that its long-acting COVID-19 neutralizing antibody therapy, the amubarvimab/romlusevimab combination, retains neutralizing activity against the Omicron BA.2 SARS-CoV-2 subvariant.

Arch Therapeutics, Inc. announced today that the third interview in the Experts in Wound Care Program, a series of interviews with key opinion leaders dedicated to advancing wound care, was conducted live in front of clinicians attending the 2022 Symposium on Advanced Wound Care.

Mainz Biomed N.V. announced that it will bring together key opinion leaders from across the Colorectal Cancer screening and diagnostics community in an event to be held during Digestive Disease Week in San Diego, California.

Immix Biopharma, Inc. announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the Company’s common stock.

Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), today announced that the first participant has been treated in an investigator-sponsored Phase 1/2 study of bomedemstat in combination with atezolizumab (Tencentriq®) during the maintenance phase of treatment in people newly diagnosed with extensive stage small cell lung cancer (ES-SCLC).

Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, May 16, 2022, at 4:30 p.m. ET to report its first quarter 2022 financial results and provide an update on its business and pipeline.

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported first quarter 2022 financial results.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2022 financial results on Monday, May 16, 2022.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today reported that the first patient has been dosed in a Phase 2a study evaluating tegoprubart in patients with IgA Nephropathy (IgAN).